DNB Asset Management AS Reduces Stock Holdings in Edwards Lifesciences Corporation $EW

DNB Asset Management AS reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 5.8% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 297,794 shares of the medical research company’s stock after selling 18,320 shares during the period. DNB Asset Management AS owned approximately 0.05% of Edwards Lifesciences worth $23,290,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Econ Financial Services Corp acquired a new stake in Edwards Lifesciences during the second quarter valued at $889,000. Pacific Capital Partners Ltd acquired a new stake in Edwards Lifesciences in the second quarter valued at approximately $1,760,000. Arkadios Wealth Advisors purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $300,000. Randolph Co Inc acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $301,000. Finally, Mirova US LLC lifted its position in shares of Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after buying an additional 1,054,301 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 1.1%

EW stock opened at $85.02 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average of $78.80 and a two-hundred day moving average of $78.04. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.21. The company has a market cap of $49.34 billion, a price-to-earnings ratio of 12.23, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a report on Friday, October 31st. Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group restated a “hold” rating and set a $84.00 price target (up previously from $81.00) on shares of Edwards Lifesciences in a research report on Monday, November 3rd. William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Finally, Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $91.39.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.